Risk/benefit ratio of perioperative OKT3 in cardiac transplantation
- 1 August 1994
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 74 (3), 261-266
- https://doi.org/10.1016/0002-9149(94)90368-9
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart TransplantationNew England Journal of Medicine, 1992
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990
- Prophylactic therapy for rejection after cardiac transplantationThe Journal of Thoracic and Cardiovascular Surgery, 1990
- Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infectionThe American Journal of Cardiology, 1989
- Cytomegalovirus Infection Is Associated With Cardiac Allograft Rejection and AtherosclerosisJAMA, 1989
- A PROSPECTIVE COMPARISON OF MURINE MONOCLONAL CD-3 (OKT3) ANTIBODY-BASED AND EQUINE ANTITHYMOCYTE GLOBULIN-BASED REJECTION PROPHYLAXIS IN CARDIAC TRANSPLANTATIONTransplantation, 1989
- RANDOMIZED PROSPECTIVE TRIAL OF OKT3 FOR EARLY PROPHYLAXIS OF REJECTION AFTER LIVER TRANSPLANTATIONTransplantation, 1989
- Complications and Monitoring of OKT3 TherapyAmerican Journal of Kidney Diseases, 1988
- Early Use of OKT3 Monoclonal Antibody in Renal Transplantation to Prevent RejectionAmerican Journal of Kidney Diseases, 1988
- INCREASED INFECTIONS ASSOCIATED WITH THE USE OF OKT3 FOR TREATMENT OF STEROID-RESISTANT REJECTION IN RENAL TRANSPLANTATION1 Pressented at the 6th Annual Meeting of the American Society of Transplant Physicians, May 1987, Chicago, ILTransplantation, 1988